<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37736101</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1217121</StartPage><MedlinePgn>1217121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1217121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1217121</ELocationID><Abstract><AbstractText Label="BACKGROUND">Lupus nephritis (LN) constitutes the most severe organ manifestations of systemic lupus erythematosus (SLE), where pathogenic T cells have been identified to play an essential role in 'helping' B cells to make autoantibodies and produce inflammatory cytokines that drive kidney injury in SLE. Regulatory T cells (Tregs), responsible for decreasing inflammation, are defective and decreased in SLE and have been associated with disease progression. We hypothesize that treatment with allogeneic, healthy Tregs derived from umbilical cord blood (UCB) may arrest such an inflammatory process and protect against kidney damage.</AbstractText><AbstractText Label="METHODS">UCB-Tregs function was examined by their ability to suppress CellTrace Violet-labeled SLE peripheral blood mononuclear cells (PBMCs) or healthy donor (HD) conventional T cells (Tcons); and by inhibiting secretion of inflammatory cytokines by SLE PBMCs. Humanized SLE model was established where female Rag2<sup>-/-</sup>&#x3b3;c<sup>-/-</sup> mice were transplanted with 3 &#xd7; 10<sup>6</sup> human SLE-PBMCs by intravenous injection on day 0, followed by single or multiple injection of UCB-Tregs to understand their impact on disease development. Mice PB was assessed weekly by flow cytometry. Phenotypic analysis of isolated cells from mouse PB, lung, spleen, liver and kidney was performed by flow cytometry. Kidney damage was assessed by quantifying urinary albumin and creatinine secretion. Systemic disease was evaluated by anti-dsDNA IgG Ab analysis as well as immunohistochemistry analysis of organs. Systemic inflammation was determined by measuring cytokine levels.</AbstractText><AbstractText Label="RESULTS"><i>In vitro</i>, UCB-Tregs are able to suppress HD Tcons and pathogenic SLE-PBMCs to a similar extent. UCB-Tregs decrease secretion of several inflammatory cytokines including IFN-&#x3b3;, IP-10, TNF-&#x3b1;, IL-6, IL-17A, and sCD40L by SLE PBMCs in a time-dependent manner, with a corresponding increase in secretion of suppressor cytokine, IL-10. <i>In vivo</i>, single or multiple doses of UCB-Tregs led to a decrease in CD8<sup>+</sup> T effector cells in different organs and a decrease in circulating inflammatory cytokines. Improvement in skin inflammation and loss of hair; and resolution of CD3<sup>+</sup>, CD8<sup>+</sup>, CD20<sup>+</sup> and Ki67<sup>+</sup> SLE-PBMC infiltration was observed in UCB-Treg recipients with a corresponding decrease in plasma anti-double stranded DNA IgG antibody levels and improved albuminuria.</AbstractText><AbstractText Label="CONCLUSIONS">UCB-Tregs can decrease inflammatory burden in SLE, reduce auto-antibody production and resolve end organ damage especially, improve kidney function. Adoptive therapy with UCB-Tregs should be explored for treatment of lupus nephritis in the clinical setting.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Lyu, Tang, Khoury, Raso, Huang, Zeng, Nishimoto, Ma, Sadeghi, Flowers and Parmar.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Mi-Ae</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Ximing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoury</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raso</LastName><ForeName>Maria Gabriela</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Meixian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimoto</LastName><ForeName>Mitsutaka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hongbing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cellenkos Inc., Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flowers</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmar</LastName><ForeName>Simrit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000419" MajorTopicYN="N">Albuminuria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">albuminuria</Keyword><Keyword MajorTopicYN="N">allogeneic</Keyword><Keyword MajorTopicYN="N">dsDNA antibodies</Keyword><Keyword MajorTopicYN="N">lupus nephritis (LN)</Keyword><Keyword MajorTopicYN="N">regulatory T cells (Tregs)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword><Keyword MajorTopicYN="N">umbilical cord blood (UCB)</Keyword></KeywordList><CoiStatement>JDK received research funding from Stemline Therapeutics, Angle, and Kiromic BioPharm. SP has an equity interest in, holds patents for, receives royalties and research funding from, and is a member of the board of directors/advisory committee for Cellenkos Inc. CRF received research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, and Eastern Cooperative Oncology Group, National Cancer Institute, and Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research and and consulting fees from AbbVie, Bayer, BeiGene, Celgene, Denovo, Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, SeaGen, and Spectrum. TS was employed by the company Cellenkos Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37736101</ArticleId><ArticleId IdType="pmc">PMC10509479</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1217121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365(22):2110&#x2013;21. doi: 10.1056/NEJMra1100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol (2020) 21(6):605&#x2013;14. doi: 10.1038/s41590-020-0677-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PM, Tsokos GC. T cell abnorMalities in the pathogenesis of systemic lupus erythematosus: an update. Curr Rheumatol Rep (2021) 23(2):12. doi: 10.1007/s11926-020-00978-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00978-5</ArticleId><ArticleId IdType="pmc">PMC8601587</ArticleId><ArticleId IdType="pubmed">33512577</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity (2014) 41(4):529&#x2013;42. doi: 10.1016/j.immuni.2014.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.10.004</ArticleId><ArticleId IdType="pmc">PMC4223692</ArticleId><ArticleId IdType="pubmed">25367570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmes J, Comd&#xfc;hr S, Akbarzadeh R, Riemekasten G, Humrich JY. Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus. Front Immunol (2022) 13:1007078. doi: 10.3389/fimmu.2022.1007078</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1007078</ArticleId><ArticleId IdType="pmc">PMC9650673</ArticleId><ArticleId IdType="pubmed">36389689</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, et al. . Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest (1996) 97(12):2866&#x2013;71. doi:&#xa0;10.1172/JCI118743</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118743</ArticleId><ArticleId IdType="pmc">PMC507381</ArticleId><ArticleId IdType="pubmed">8675699</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C, et al. . Lupus nephritis. Nat Rev Dis Primers (2020) 6(1):7. doi: 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 6(4):345&#x2013;52. doi: 10.1038/ni1178</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1178</ArticleId><ArticleId IdType="pubmed">15785760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057&#x2013;61. doi: 10.1126/science.1079490</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079490</ArticleId><ArticleId IdType="pubmed">12522256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4(4):330&#x2013;6. doi: 10.1038/ni904</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni904</ArticleId><ArticleId IdType="pubmed">12612578</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 117(3):289&#x2013;300. doi: 10.1111/j.1365-2567.2005.02317.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2005.02317.x</ArticleId><ArticleId IdType="pmc">PMC1782226</ArticleId><ArticleId IdType="pubmed">16476048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellor-Pita S, Citores MJ, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu JL, et al. . Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis (2006) 65(4):553&#x2013;4. doi: 10.1136/ard.2005.044974</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.044974</ArticleId><ArticleId IdType="pmc">PMC1798083</ArticleId><ArticleId IdType="pubmed">16531555</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X, Yuan X, Zheng Y, Wang W, Shan J, Lin F, et al. . Increased CD45RA+ FoxP3(low) regulatory T cells with impaired suppressive function in patients with systemic lupus erythematosus. PloS One (2012) 7(4):e34662. doi:&#xa0;10.1371/journal.pone.0034662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034662</ArticleId><ArticleId IdType="pmc">PMC3323568</ArticleId><ArticleId IdType="pubmed">22506043</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 178(4):2579&#x2013;88. doi: 10.4049/jimmunol.178.4.2579</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.4.2579</ArticleId><ArticleId IdType="pubmed">17277168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, et al. . Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol (2008) 20(7):861&#x2013;8. doi: 10.1093/intimm/dxn044</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxn044</ArticleId><ArticleId IdType="pubmed">18469329</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Liu Q, Zong D, Zhang W, Zuo Z, Yu Q, et al. . Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus. Cell Rep (2022) 41(6):111606. doi: 10.1016/j.celrep.2022.111606</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111606</ArticleId><ArticleId IdType="pubmed">36351407</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC, et al. . Pathogenesis of human systemic lupus erythematosus: A cellular perspective. Trends Mol Med (2017) 23(7):615&#x2013;35. doi: 10.1016/j.molmed.2017.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.05.006</ArticleId><ArticleId IdType="pmc">PMC5650102</ArticleId><ArticleId IdType="pubmed">28623084</ArticleId></ArticleIdList></Reference><Reference><Citation>Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, et al. . Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum (2008) 58(7):2120&#x2013;30. doi: 10.1002/art.23556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23556</ArticleId><ArticleId IdType="pubmed">18576316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenbrock K, Rauen T. T cell dysregulation in SLE. Clin Immunol (2022) 239:109031. doi: 10.1016/j.clim.2022.109031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109031</ArticleId><ArticleId IdType="pubmed">35526790</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, et al. . Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy (2014) 16(1):90&#x2013;100. doi: 10.1016/j.jcyt.2013.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2013.07.009</ArticleId><ArticleId IdType="pmc">PMC4124936</ArticleId><ArticleId IdType="pubmed">24480547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, et al. . Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget (2018) 9(86):35611&#x2013;22. doi: 10.18632/oncotarget.26242</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.26242</ArticleId><ArticleId IdType="pmc">PMC6235025</ArticleId><ArticleId IdType="pubmed">30479692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu MA, Huang M, Zeng K, Li L, Khoury JD, Nishimoto M, et al. . Allogeneic cord blood regulatory T cells can resolve lung inflammation. Cytotherapy (2023) 25(3):245&#x2013;53. doi: 10.1016/j.jcyt.2022.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2022.10.009</ArticleId><ArticleId IdType="pubmed">36437190</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladstone DE, Kim BS, Mooney K, Karaba AH, D'Alessio FR. Regulatory T cells for treating patients with COVID-19 and acute respiratory distress syndrome: two case reports. Ann Intern Med (2020) 173(10):852&#x2013;3. doi: 10.7326/L20-0681</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L20-0681</ArticleId><ArticleId IdType="pmc">PMC7370819</ArticleId><ArticleId IdType="pubmed">32628535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladstone DE DAF, Howard C, Lyu MA, Mock JR, Gibbs KW, Abrams D, et al. . Randomized, double blinded, placebo controlled trial of allogeneic cord blood T-regulatory cell for treatment of COVID-19 acute respiratory distress syndrome. Blood Adv (2023) 7(13):3075&#x2013;9. doi: 10.1182/bloodadvances.2022009619</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022009619</ArticleId><ArticleId IdType="pmc">PMC10043947</ArticleId><ArticleId IdType="pubmed">36961352</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade D, Redecha PB, Vukelic M, Qing X, Perino G, Salmon JE, et al. . Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rgamma-/- mice: a promising model for studying human disease. Arthritis Rheum (2011) 63(9):2764&#x2013;73. doi: 10.1002/art.30424</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30424</ArticleId><ArticleId IdType="pmc">PMC3168580</ArticleId><ArticleId IdType="pubmed">21560114</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol (2020) 20(3):158&#x2013;72. doi: 10.1038/s41577-019-0232-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0232-6</ArticleId><ArticleId IdType="pmc">PMC7814338</ArticleId><ArticleId IdType="pubmed">31811270</ArticleId></ArticleIdList></Reference><Reference><Citation>Uva L, Miguel D, Pinheiro C, Freitas JP, Gomes MM, Filipe P, et al. . Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis (2012) 2012:834291. doi: 10.1155/2012/834291</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/834291</ArticleId><ArticleId IdType="pmc">PMC3410306</ArticleId><ArticleId IdType="pubmed">22888407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S, Chan TM. Mechanisms of kidney injury in lupus nephritis - the role of anti-dsDNA antibodies. Front Immunol (2015) 6:475. doi: 10.3389/fimmu.2015.00475</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00475</ArticleId><ArticleId IdType="pmc">PMC4569852</ArticleId><ArticleId IdType="pubmed">26441980</ArticleId></ArticleIdList></Reference><Reference><Citation>Birmingham DJ, Rovin BH, Shidham G, Bissell M, Nagaraja HN, Hebert LA, et al. . Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications. Clin J Am Soc Nephrol (2008) 3(4):1028&#x2013;33. doi: 10.2215/CJN.04761107</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04761107</ArticleId><ArticleId IdType="pmc">PMC2440287</ArticleId><ArticleId IdType="pubmed">18450925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Cai B, Feng W, Yang B, Huang Z, Zuo C, et al. . Double positive CD4+CD8+ T cells: key suppressive role in the production of autoantibodies in systemic lupus erythematosus. Indian J Med Res (2014) 140(4):513&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277137</ArticleId><ArticleId IdType="pubmed">25488445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao YP, Tseng FY, Chao CW, Chen MH, Yeh YC, Abdulkareem BO, et al. . NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. J Clin Invest (2023) 133(3):1&#x2013;19. doi: 10.1172/JCI157272</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157272</ArticleId><ArticleId IdType="pmc">PMC9888378</ArticleId><ArticleId IdType="pubmed">36719379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji-Takayama K, Suzuki M, Yamamoto M, Harashima A, Okochi A, Otani T, et al. . The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol (2008) 181(6):3897&#x2013;905. doi: 10.4049/jimmunol.181.6.3897</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.6.3897</ArticleId><ArticleId IdType="pubmed">18768844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudensky AY. Regulatory T cells and foxp3. Immunol Rev (2011) 241(1):260&#x2013;8. doi: 10.1111/j.1600-065X.2011.01018.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2011.01018.x</ArticleId><ArticleId IdType="pmc">PMC3077798</ArticleId><ArticleId IdType="pubmed">21488902</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. . Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2020) 79(1):141&#x2013;9. doi: 10.1136/annrheumdis-2019-215396</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215396</ArticleId><ArticleId IdType="pmc">PMC6937406</ArticleId><ArticleId IdType="pubmed">31537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, et al. . Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis (2022) 81(12):1685&#x2013;94. doi: 10.1136/ard-2022-222501</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222501</ArticleId><ArticleId IdType="pubmed">35973803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicholas N, et al. . Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol (2013) 1(4):295&#x2013;305. doi: 10.1016/S2213-8587(13)70113-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(13)70113-X</ArticleId><ArticleId IdType="pubmed">24622415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader L, Boyman O, Raeber ME. Low-dose interleukin-2 for the treatment of systemic lupus erythematosus: A systematic review and meta-analysis. medRxiv (2022). doi: 10.1101/2022.12.02.22283038</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.02.22283038</ArticleId></ArticleIdList></Reference><Reference><Citation>Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol (2009) 131(2):298&#x2013;307. doi: 10.1016/j.clim.2008.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.12.008</ArticleId><ArticleId IdType="pubmed">19211307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, et al. . Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. Arthritis Rheum (2011) 63(6):1698&#x2013;706. doi: 10.1002/art.30313</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30313</ArticleId><ArticleId IdType="pubmed">21370226</ArticleId></ArticleIdList></Reference><Reference><Citation>al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol (1993) 13(1):58&#x2013;67. doi: 10.1007/BF00920636</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00920636</ArticleId><ArticleId IdType="pubmed">8445045</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Li M, Wang Z, Wang J. IFN-gamma mediates the development of systemic lupus erythematosus. BioMed Res Int 2020 (2020) 2020:7176515. doi:&#xa0;10.1155/2020/7176515</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7176515</ArticleId><ArticleId IdType="pmc">PMC7586164</ArticleId><ArticleId IdType="pubmed">33123584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75(2):163&#x2013;89. doi: 10.1189/jlb.0603252</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0603252</ArticleId><ArticleId IdType="pubmed">14525967</ArticleId></ArticleIdList></Reference><Reference><Citation>Olalekan SA, Cao Y, Hamel KM, Finnegan A. B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol (2015) 45(4):988&#x2013;98. doi: 10.1002/eji.201445036</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201445036</ArticleId><ArticleId IdType="pmc">PMC4438566</ArticleId><ArticleId IdType="pubmed">25645456</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Zhang S, Wang J. IFN-gamma, should not be ignored in SLE. Front Immunol (2022) 13:954706. doi: 10.3389/fimmu.2022.954706</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.954706</ArticleId><ArticleId IdType="pmc">PMC9399831</ArticleId><ArticleId IdType="pubmed">36032079</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 377(9767):721&#x2013;31. doi: 10.1016/S0140-6736(10)61354-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov&#xe1; D, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 63(12):3918&#x2013;30. doi: 10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougiakakos D, Kr&#xf6;nke G, V&#xf6;lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. . CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med (2021) 385(6):567&#x2013;9. doi: 10.1056/NEJMc2107725</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107725</ArticleId><ArticleId IdType="pubmed">34347960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima KI, Sakan H, et al. . Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol (2010) 299(1):F207&#x2013;16. doi: 10.1152/ajprenal.00482.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00482.2009</ArticleId><ArticleId IdType="pubmed">20410215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose J, Redecke V, Guy C, Zhou J, Wu R, Ippagunta SK, et al. . Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. J Clin Invest (2019) 129(6):2251&#x2013;65. doi: 10.1172/JCI125116</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI125116</ArticleId><ArticleId IdType="pmc">PMC6546471</ArticleId><ArticleId IdType="pubmed">31033479</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP, et al. . Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol (2002) 103(1):54&#x2013;62. doi: 10.1006/clim.2001.5172</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clim.2001.5172</ArticleId><ArticleId IdType="pubmed">11987985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong KO, Tan AW, Thong BY, Lian TY, Cheng YK, Teh CL, et al. . Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol (2009) 156(1):134&#x2013;40. doi: 10.1111/j.1365-2249.2009.03880.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.03880.x</ArticleId><ArticleId IdType="pmc">PMC2673751</ArticleId><ArticleId IdType="pubmed">19175619</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 10(1):202. doi: 10.1186/ar2341</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2341</ArticleId><ArticleId IdType="pmc">PMC2374473</ArticleId><ArticleId IdType="pubmed">18226185</ArticleId></ArticleIdList></Reference><Reference><Citation>Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR, et al. . Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol (1991) 147(1):117&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">2051017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. . Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum (2009) 60(5):1472&#x2013;83. doi: 10.1002/art.24499</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24499</ArticleId><ArticleId IdType="pubmed">19404966</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P, Italiani P, Pratesi F, Puxeddu I, Boraschi D. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev (2020) 19(9):102617. doi: 10.1016/j.autrev.2020.102617</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102617</ArticleId><ArticleId IdType="pubmed">32663626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther (2011) 13(6):250. doi: 10.1186/ar3528</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3528</ArticleId><ArticleId IdType="pmc">PMC3334648</ArticleId><ArticleId IdType="pubmed">22192660</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalta D, Bizzaro N, Bassi N, Zen M, Gatto M, Ghirardello A, et al. . Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PloS One (2013) 8(8):e71458. doi: 10.1371/journal.pone.0071458</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071458</ArticleId><ArticleId IdType="pmc">PMC3741383</ArticleId><ArticleId IdType="pubmed">23951169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Zhao L, Wang C, Shang J, Miao Y, Dong Y, et al. . Anti-double-stranded DNA isotypes and anti-C1q antibody improve the diagnostic specificity of systemic lupus erythematosus. Dis Markers (2018) 2018:452847. doi: 10.1155/2018/4528547</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4528547</ArticleId><ArticleId IdType="pmc">PMC6180986</ArticleId><ArticleId IdType="pubmed">30363714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>